Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6% – What’s Next?

Shares of Rapport Therapeutics (NASDAQ:RAPP) traded down 6% on Tuesday . The company traded as low as $22.40 and last traded at $22.56. 42,321 shares were traded during trading, a decline of 72% from the average session volume of 153,353 shares. The stock had previously closed at $24.00.

Rapport Therapeutics Price Performance

The business’s 50 day moving average price is $23.12.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently bought and sold shares of RAPP. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics during the third quarter worth $31,000. BNP Paribas Financial Markets acquired a new stake in Rapport Therapeutics in the third quarter worth about $34,000. SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics during the third quarter worth about $101,000. Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the second quarter valued at about $116,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $117,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.